Gale R P, Foon K A, Cline M J, Zighelboim J
Ann Intern Med. 1981 Jun;94(6):753-7. doi: 10.7326/0003-4819-94-6-753.
A complete remission rate of 82% was obtained in a group of 68 patients with acute myelogenous leukemia treated with a high-dose induction chemotherapy (TAD) consisting of 7-day courses of 6-thioguanine, cytarabine, and daunorubicin. The patients who achieved remission received intensive consolidation chemotherapy and were randomized to receive maintenance chemotherapy with or without immunotherapy. Median remission duration was 13 months and median survival, 21 months. Neither central nervous system prophylaxis nor the addition of immunotherapy to the maintenance regimen prolonged remissions or improved survival. Age, sex, and subclassification of acute myelogenous leukemia had no effect on the remission rate or survival. These data indicate that a large proportion of patients with acute myelogenous leukemia can achieve remission with intensive induction chemotherapy. Attempts to prolong remission have been less successful.
一组68例急性髓性白血病患者接受了由6 - 硫鸟嘌呤、阿糖胞苷和柔红霉素组成的7天疗程大剂量诱导化疗（TAD），完全缓解率达82%。达到缓解的患者接受了强化巩固化疗，并被随机分为接受或不接受免疫治疗的维持化疗组。中位缓解持续时间为13个月，中位生存期为21个月。中枢神经系统预防措施以及在维持方案中添加免疫治疗均未延长缓解期或改善生存期。急性髓性白血病的年龄、性别和亚分类对缓解率或生存期均无影响。这些数据表明，大部分急性髓性白血病患者可通过强化诱导化疗实现缓解。延长缓解期的尝试成效较差。
